Join Growin Stock Community!

Cullinan therapeutics, inc.CGEM.US Overview

US StockHealthcare
(No presentation for CGEM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CGEM AI Insights

CGEM Overall Performance

CGEM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CGEM Recent Performance

1.65%

Cullinan therapeutics, inc.

1.63%

Avg of Sector

0.63%

S&P500

CGEM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CGEM Key Information

CGEM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CGEM Profile

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Price of CGEM

CGEM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CGEM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.67
PE Ratio (TTM)
-
Forward PE
6.30
PS Ratio (TTM)
26.88
PB Ratio
2.03
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.67
PE Ratio (TTM)
-
Forward PE
6.30
PS Ratio (TTM)
26.88
PB Ratio
2.03
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CGEM's latest earnings report released?

    The most recent financial report for Cullinan therapeutics, inc. (CGEM) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CGEM's short-term business performance and financial health. For the latest updates on CGEM's earnings releases, visit this page regularly.

  • How much cash does CGEM have?

    At the end of the period, Cullinan therapeutics, inc. (CGEM) held Total Cash and Cash Equivalents of 103.34M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CGEM's EPS continuing to grow?

    According to the past four quarterly reports, Cullinan therapeutics, inc. (CGEM)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.77. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CGEM?

    Cullinan therapeutics, inc. (CGEM)'s Free Cash Flow (FCF) for the period is -36.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.13% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.